<DOC>
	<DOCNO>NCT02714855</DOCNO>
	<brief_summary>The present study conduct assess follow research question real-life condition France : What patient disease characteristic , comorbidities treatment history NVAF patient initiate new Anticoagulant ( AC ) treatment , accord treatment currently available prescribed ( apixaban , NOACs , VKAs ) , AC-naive patient profile different one treatment pattern another initiate new AC treatment ? What HCP 's reason discontinue previous AC strategy initiate choose newly initiate AC treatment NVAF patient ? What condition newly-initiated apixaban prescription NVAF patient : prescriber , proportion naïve/experienced patient , daily dosage number daily dos ?</brief_summary>
	<brief_title>Apixaban Prevention Stroke Systemic Embolism Patients With Atrial Fibrillation Real-Life Setting France</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<criteria>Patients age ≥ 18 year Diagnosed non valvular atrial fibrillation ( NVAF ) Prescribed newly initiate AC treatment ( apixaban , NOACs VKAs ) . Newly initiate AC treatment define AC treatment initiate within past 3 month , include day enrolment Patients atrial fibrillation ( AF ) due reversible cause Patients diagnosis VAF . The term VAF use imply AF relate rheumatic valvular disease ( predominantly mitral stenosis ) prosthetic heart valves Patients participate ongoing clinical trial AF</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>